Work

The emergence of neoadjuvant immune‐ over BRAF therapy in melanoma

Year: 2024

Type: article

Abstract: Neoadjuvant therapy has emerged in high‐risk stage III melanoma with immunotherapy improving long‐term outcomes when compared with BRAF and MEK inhibition. Unmet needs remain surrounding optimal immunotherapy combinations, selection biomarkers, and deintensification of treatment.

Source: Cancer

DOI: 10.1002/cncr.35490

Authors: Elisa A. Rozeman, Jason J. Luke

Institutions: The Netherlands Cancer Institute, University Medical Center Utrecht, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute